Teva’s Generic Zocor Exclusivity Upheld

Law360, New York (June 23, 2006, 12:00 AM EDT) -- Generic drug maker Sandoz Inc.’s efforts to prevent Teva Pharmaceuticals from marketing its generic version of cholesterol drug Zocor have been thwarted, after a judge upheld Teva’s right to a 180-day period of marketing exclusivity.

Sandoz, the generics unit of Novartis, filed a suit in the U.S. District Court for the District of Columbia asking the court to prevent Teva from releasing its generic until Sandoz receives U.S. Food and Drug Administration approval for its version.

The complaint, filed against the FDA, challenged the agency’s “decision...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.